Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) Director Maha Katabi sold 81,009 shares of the business’s stock in a transaction dated Thursday, March 21st. The stock was sold at an average price of $44.20, for a total transaction of $3,580,597.80. Following the completion of the sale, the director now owns 3,547,437 shares in the company, valued at $156,796,715.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Maha Katabi also recently made the following trade(s):
- On Monday, March 25th, Maha Katabi sold 340,000 shares of Vera Therapeutics stock. The shares were sold at an average price of $40.50, for a total transaction of $13,770,000.00.
- On Tuesday, January 30th, Maha Katabi bought 161,290 shares of Vera Therapeutics stock. The stock was purchased at an average price of $31.00 per share, for a total transaction of $4,999,990.00.
Vera Therapeutics Stock Performance
VERA stock opened at $43.83 on Thursday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 6.97 and a current ratio of 6.97. The stock has a market capitalization of $2.30 billion, a price-to-earnings ratio of -19.14 and a beta of 1.10. Vera Therapeutics, Inc. has a 1 year low of $5.95 and a 1 year high of $50.78. The stock’s fifty day moving average is $39.76 and its two-hundred day moving average is $22.93.
Analyst Upgrades and Downgrades
View Our Latest Stock Analysis on Vera Therapeutics
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of VERA. Commodore Capital LP increased its holdings in shares of Vera Therapeutics by 93.0% during the second quarter. Commodore Capital LP now owns 5,450,000 shares of the company’s stock valued at $87,472,000 after purchasing an additional 2,625,971 shares during the period. FMR LLC increased its holdings in shares of Vera Therapeutics by 39.7% during the first quarter. FMR LLC now owns 5,796,259 shares of the company’s stock valued at $44,979,000 after purchasing an additional 1,647,613 shares during the period. Schroder Investment Management Group acquired a new position in shares of Vera Therapeutics during the fourth quarter valued at $17,087,000. Point72 Asset Management L.P. acquired a new position in shares of Vera Therapeutics during the fourth quarter valued at $15,139,000. Finally, BlackRock Inc. increased its holdings in shares of Vera Therapeutics by 53.9% during the second quarter. BlackRock Inc. now owns 2,170,134 shares of the company’s stock valued at $34,831,000 after purchasing an additional 759,864 shares during the period. 99.21% of the stock is owned by institutional investors and hedge funds.
About Vera Therapeutics
Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis.
Read More
- Five stocks we like better than Vera Therapeutics
- What is a SEC Filing?
- Best Bear Market Funds: Top 3 Investment Options to Consider
- When to Sell a Stock for Profit or Loss
- Is DraftKings A Good Bet Ahead of Q1 Earnings?
- Overbought Stocks Explained: Should You Trade Them?
- Mid-Cap Stocks to Outperform the Market This Cycle
Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.